Enzo Biochem (ENZ)

[surf1944]

Enzo Biochem gets rights to potential HPV test
Enzo Biochem plans to market test designed to find cervical cancer risk in HPV patients

On Friday June 10, 2011, 2:45 pm EDT

NEW YORK (AP) -- Enzo Biochem Inc. said Friday that it agreed to acquire the marketing rights to a human papillomavirus test developed by IncellDx Inc.

The company said the test is designed to assess the likelihood that a patient with HPV will develop cervical cancer. Regulators have not yet cleared the test, and Enzo said it will conduct studies of the test before seeking New York State approval. The company said it will be the first New York licensed reference laboratory to offer the test.

Enzo did not disclose financial terms of the deal.

HPV is responsible for about 70 percent of all cervical cancer cases. The virus spreads through sexual contact.

Enzo Biochem reported its fiscal third-quarter results on Thursday. It posted a smaller quarterly loss and said revenue rose 9 percent.

In afternoon trading Friday, the stock rose 18 cents, or 4.9 percent, to $3.89.